Robert Pordy

16.7k total citations · 8 hit papers
107 papers, 6.6k citations indexed

About

Robert Pordy is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Economics and Econometrics. According to data from OpenAlex, Robert Pordy has authored 107 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Surgery, 53 papers in Cardiology and Cardiovascular Medicine and 40 papers in Economics and Econometrics. Recurrent topics in Robert Pordy's work include Lipoproteins and Cardiovascular Health (82 papers), Health Systems, Economic Evaluations, Quality of Life (30 papers) and Lipid metabolism and disorders (29 papers). Robert Pordy is often cited by papers focused on Lipoproteins and Cardiovascular Health (82 papers), Health Systems, Economic Evaluations, Quality of Life (30 papers) and Lipid metabolism and disorders (29 papers). Robert Pordy collaborates with scholars based in United States, France and Canada. Robert Pordy's co-authors include Christelle Lorenzato, Umesh Chaudhari, Jennifer G. Robinson, John J.P. Kastelein, Jean Bergeron, Frederick J. Raal, Erik S.G. Stroes, Michel Farnier, Daniel Gaudet and Gisle Langslet and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Robert Pordy

102 papers receiving 6.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

2015 1.7k citations Erik S.G. Stroes, Frederick J. Raal et al. New England Journal of Medicine profile →
Evinacumab for Homozygous Familial Hypercholesterolemia

2020 470 citations Frederick J. Raal, Robert S. Rosenson et al. New England Journal of Medicine profile →
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

2012 463 citations Daniel Gaudet, Robert Pordy et al. profile →
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

2015 418 citations John J.P. Kastelein, G. Kees Hovingh et al. European Heart Journal profile →
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

2015 345 citations Robert Pordy, Daniel A. Gipe et al. Journal of clinical lipidology profile →
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

2015 316 citations Robert Pordy et al. European Heart Journal profile →
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

2015 291 citations Robert Pordy et al. profile →
Evinacumab in Patients with Refractory Hypercholesterolemia

2020 215 citations Robert S. Rosenson, Seth J. Baum et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Robert Pordy

Since Specialization

Citations

This map shows the geographic impact of Robert Pordy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Pordy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Pordy more than expected).

Fields of papers citing papers by Robert Pordy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Pordy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Pordy. The network helps show where Robert Pordy may publish in the future.

Co-authorship network of co-authors of Robert Pordy

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Pordy. A scholar is included among the top collaborators of Robert Pordy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Pordy. Robert Pordy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment With Evinacumab Links a New Pathogenic Variant in the LPL Gene to Persistent Chylomicronemia 2025 ·Journal of the Endocrine Society ·(unknown), Poulabi Banerjee, Diane Brisson, Robert Pordy, Daniel Gaudet	2
2	Evinacumab in patients aged 5–17 years with homozygous familial hypercholesterolemia 2025 ·Atherosclerosis ·(unknown), Eliot A. Brinton, (unknown), Frederick J. Raal, (unknown), (unknown), (unknown), Jean Bergeron, (unknown), (unknown), Shazia Ali, (unknown), Robert Pordy, Xue-Qiao Zhao, (unknown)	0
3	Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial 2025 ·Journal of clinical lipidology ·Robert S. Rosenson, Richard T. De George, Robert J. Sanchez, Xue-Qiao Zhao, Manish P. Ponda, (unknown), Robert Pordy	1
4	Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia 2025 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Robert Dingman, Jeanne Mendell, Katy C. Norman, Richard T. De George, Xue‐Qiao Zhao, Robert Pordy, (unknown), Wendy S. Putnam, Geetha Raghuveer, Brian W. McCrindle, Elena Fornari, Ivo Barić, Shubha Srinivasan, (unknown), Eliot A. Brinton, John D. Davis, (unknown), Lutz Harnisch	1
5	Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study 2024 ·Journal of clinical lipidology ·Vera Bittner, Gregory G. Schwartz, Deepak L. Bhatt, Terrance Chua, (unknown), Rafael Díaz, Shaun G. Goodman, Robert A. Harrington, J. Wouter Jukema, Jennifer McGinniss, Robert Pordy, (unknown), Michel Scemama, Harvey D. White, Philippe Gabríel Steg, Michael Szarek	9
6	34-OR: The Effect of Combined Activin A and Myostatin Blockade on Body Composition—A Phase 1 Trial 2024 ·Diabetes ·Dinko González Trotter, (unknown), (unknown), (unknown), Prodromos Parasoglou, Anita Boyapati, Kusha Mohammadi, (unknown), (unknown), Jason Mastaitis, (unknown), (unknown), John D. Davis, (unknown), Robert Pordy	2
7	Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia 2023 ·Circulation ·Albert Wiegman, Susanne Greber‐Platzer, Shazia Ali, M. Doortje Reijman, Eliot A. Brinton, Min‐Ji Charng, Shubha Srinivasan, Carissa M. Baker‐Smith, Seth J. Baum, Julie A. Brothers, Jacob Hartz, Patrick M. Moriarty, Jeanne Mendell, (unknown), Poulabi Banerjee, Richard T. De George, Boaz Hirshberg, Robert Pordy	41
8	CLINICAL TRIAL WITH THE ANGPTL3 MONOCLONAL ANTIBODY EVINACUMAB IDENTIFIES A NEW RARE CHYLOMICRONEMIA CAUSING VARIANT IN THE LPL GENE 2023 ·Canadian Journal of Cardiology ·(unknown), Robert Pordy, Poulabi Banerjee, Daniel Gaudet	1
9	Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials 2023 ·Cancer Medicine ·Kusha Mohammadi, (unknown), Gregory G. Schwartz, Philippe Gabríel Steg, Michael Szarek, Garen Manvelian, Robert Pordy, Sergio Fazio, Gregory P. Geba	3
10	The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia 2023 ·JACC Advances ·Frederick J. Raal, Robert S. Rosenson, Laurens F. Reeskamp, John J.P. Kastelein, Paolo Rubba, P. Barton Duell, Masahiro Koseki, Erik S.G. Stroes, Shazia Ali, Poulabi Banerjee, Kuo‐Chen Chan, Nagwa Khilla, Jennifer McGinniss, Robert Pordy, Yi Zhang, Daniel Gaudet	15
11	Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome 2023 ·Canadian Journal of Cardiology ·(unknown), Michael Szarek, Marco Valgimigli, Md. Shahidul Islam, Andreas M. Zeiher, (unknown), (unknown), Chern‐En Chiang, Rafael Díaz, Shaun G. Goodman, Nina Gotcheva, Robert A. Harrington, J. Wouter Jukema, Hyo‐Soo Kim, (unknown), João Morais, Robert Pordy, Michel Scemama, (unknown), Gregory G. Schwartz, Philippe Gabríel Steg, (unknown), (unknown), Rafael Dı́az, (unknown)	3
12	Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial 2023 ·European Heart Journal ·Gregory G. Schwartz, Michael Szarek, Deepak L. Bhatt, Vera Bittner, Maja Bujas‐Bobanovic, Rafael Díaz, Sergio Fazio, Zlatko Fras, Shaun G. Goodman, Robert A. Harrington, J. Wouter Jukema, Garen Manvelian, Robert Pordy, Kausik K. Ray, Michel Scemama, Harvey D. White, Philippe Gabríel Steg, (unknown)	27
13	Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes 2022 ·Journal of clinical lipidology ·Patrick M. Moriarty, Philippe Gabríel Steg, Jennifer McGinniss, Andreas M. Zeiher, Harvey D. White, Garen Manvelian, Robert Pordy, (unknown), J. Wouter Jukema, Robert A. Harrington, (unknown), (unknown), Shaun G. Goodman, Rafael Díaz, Vera Bittner, Deepak L. Bhatt, Michael Szarek, Gregory G. Schwartz	2
14	Alirocumab after acute coronary syndrome in patients with a history of heart failure 2021 ·European Heart Journal ·Harvey D. White, Gregory G. Schwartz, Michael Szarek, Deepak L. Bhatt, Vera Bittner, Chern‐En Chiang, Rafael Díaz, Shaun G. Goodman, J. Wouter Jukema, (unknown), Neha J. Pagidipati, Robert Pordy, Arsen Ristić, Andreas M. Zeiher, Daniel Wojdyla, Philippe Gabríel Steg, (unknown)	24
15	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol 2021 ·Circulation ·Gregory G. Schwartz, Philippe Gabríel Steg, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, Shaun G. Goodman, J. Wouter Jukema, Yong-Un Kim, (unknown), Garen Manvelian, Robert Pordy, (unknown), Harvey D. White, Michael Szarek	56
16	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial 2020 ·European Heart Journal ·(unknown), Philippe Gabríel Steg, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, Shaun G. Goodman, J. Wouter Jukema, Yong-Un Kim, (unknown), Christian Mueller, Alexander Parkhomenko, Robert Pordy, Piyamitr Sritara, Michael Szarek, Harvey D. White, Andreas M. Zeiher, Gregory G. Schwartz, (unknown)	45
17	Evinacumab for Homozygous Familial Hypercholesterolemia breakdown → 2020 ·New England Journal of Medicine ·Frederick J. Raal, Robert S. Rosenson, Laurens F. Reeskamp, G. Kees Hovingh, John J.P. Kastelein, Paolo Rubba, Shazia Ali, Poulabi Banerjee, Kuo‐Chen Chan, Daniel A. Gipe, Nagwa Khilla, Robert Pordy, David M. Weinreich, George D. Yancopoulos, Yi Zhang, Daniel Gaudet	470
18	Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity 2019 ·Arteriosclerosis Thrombosis and Vascular Biology ·Poulabi Banerjee, Kuo‐Chen Chan, (unknown), Asier Benito‐Vicente, Ana Catarina Alves, Kepa B. Uribe, Mafalda Bourbon, Paul J. Skiba, Robert Pordy, Daniel A. Gipe, Daniel Gaudet, César Martı́n	64
19	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis 2019 ·European Heart Journal ·Peter Sinnaeve, Gregory G. Schwartz, Daniel Wojdyla, Marco Alings, Deepak L. Bhatt, Vera Bittner, Chern‐En Chiang, R. Correa, Rafael Díaz, Maria Dorobanţu, Shaun G. Goodman, J. Wouter Jukema, Yong-Un Kim, Robert Pordy, Matthew T. Roe, Rody G. Sy, Michael Szarek, Harvey D. White, Andreas M. Zeiher, Philippe Gabríel Steg, (unknown)	59
20	Abstract 19133: Inhibition of ANGPTL3 by Evinacumab Reduced Triglycerides (TGs) and LDL-C in Subjects Presenting With Modest Elevations in TGs and/or LDL-C, Recapitulating the Hypolipidemic Effects of Loss-of-Function (LoF) Mutations of ANGPTL3 2016 ·Circulation ·Richard L. Dunbar, (unknown), Daniel A. Gipe, Robert Pordy, William J. Sasiela, Scott Mellis, Poulabi Banerjee	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact